Objective:

Evaluate the effectiveness of a treatment combined with topical dorzolamide in patients with cystoid macular edema after cataract surgery.

Methods:

An experimental study was conducted of patients attending the Vitreous-Retina Service at Ramón Pando Ferrer Cuban Institute of Ophthalmology in the year 2018. The sample was divided into a case group (dorzolamide and conventional treatment) and a control group (conventional treatment), and evaluated at the initial consultation and after one month of treatment.

Results:

Mean age was 60.73 ± 11.25 years. A predominance was found of the female sex (53.33%), affected right eye (60.00%), postsurgical time ≤ 3 months (63.33%), and no associated risk factors (56.67%). Edema without associated alterations was more common (80.00%). Mean macular thickness decreased in both groups (from 529.27 ± 183.58 to 349.93 ± 221.35 in cases and from 498.87 ± 213.26 to 373.53 ± 215.51 in controls). Variation was greater in the case group (179.33 p= 0.008). Visual acuity increased in both groups. A higher percentage of eyes with improved vision was found in the case group (52.38%). Visual acuity improvement was related to macular thickness recovery.

Conclusions:

In cases of cystoid macular edema after cataract surgery with indication of topical treatment with anti-inflammatories, the combination with dorzolamide is effective to reduce macular thickness and improve corrected visual acuity.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )